Literature DB >> 7965800

Inhibition of neurally mediated nonadrenergic, noncholinergic contractions of guinea pig bronchus by isozyme-selective phosphodiesterase inhibitors.

B J Undem1, S N Meeker, J Chen.   

Abstract

We studied the effect of inhibiting phosphodiesterase (PDE) isozyme types III, IV and V on the cholinergic and noncholinergic (tachykinergic) contractile responses to electrical field stimulation (EFS) in the guinea pig isolated bronchus. SKF 94836, a PDE III inhibitor, had a slight (approximately 30%) but significant inhibitory effect on the noncholinergic contractions. Rolipram, an inhibitor of PDE IV isozymes, dramatically inhibited the noncholinergic contractions by nearly 70%. The EC50 for rolipram was approximately 20 nM. Rolipram (1 microM) had no effect on contractions elicited by either capsaicin or neurokinin A. EFS, but not direct vagus nerve stimulation, elicits small nonadrenergic, noncholinergic relaxations of the bronchus that were potentiated by rolipram. Rolipram had the same inhibitory effect on EFS- and vagus nerve stimulation-induced noncholinergic contractions. The effect of rolipram was mimicked by another PDE IV inhibitor, RO-201724. Inhibition of PDE V with zaprinast (3 microM) had no effect on the tachykinergic contractile response. None of the PDE inhibitors affected the EFS-induced cholinergic contractions. The data suggest that the contraction due to stimulation of tachykinergic fibers is significantly reduced by selective inhibition of PDE IV and, to a lesser extent, PDE III isozymes. This is unlikely to be due to functional antagonism at the level of the smooth muscle. It is also unlikely to be due to potentiation of the nonadrenergic relaxant response to nerve stimulation. Rather, the data are in agreement with the hypothesis that selective inhibition of PDE isozymes leads to inhibition of electrically evoked tachykinin release from capsaicin-sensitive fibers in the guinea pig bronchus.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7965800

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Inhibition of pulmonary eosinophilia and airway hyperresponsiveness in allergic mice by rolipram: involvement of endogenously released corticosterone and catecholamines.

Authors:  T T Kung; Y Crawley; B Luo; S Young; W Kreutner; R W Chapman
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

2.  Naloxone blocks endomorphin-1 but not endomorphin-2 induced inhibition of tachykinergic contractions of guinea-pig isolated bronchus.

Authors:  A Fischer; B J Undem
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

3.  The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4.

Authors:  B Hughes; D Howat; H Lisle; M Holbrook; T James; N Gozzard; K Blease; P Hughes; R Kingaby; G Warrellow; R Alexander; J Head; E Boyd; M Eaton; M Perry; M Wales; B Smith; R Owens; C Catterall; S Lumb; A Russell; R Allen; M Merriman; D Bloxham; G Higgs
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

Review 4.  Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.

Authors:  Domenico Spina
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 5.  Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease.

Authors:  Katharine H Banner; Neil J Press
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

6.  Regulation by phosphodiesterase isoenzymes of non-adrenergic non-cholinergic contraction in guinea-pig isolated main bronchus.

Authors:  D Spina; S Harrison; C P Page
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

Review 7.  Treating COPD with PDE 4 inhibitors.

Authors:  William M Brown
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

Review 8.  Sensory nerves and airway irritability.

Authors:  B J Canning; D Spina
Journal:  Handb Exp Pharmacol       Date:  2009
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.